Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

One Global Service Provider Li Share Price

₹ 354 -7.20 (-1.99%)

Apr 15 2025 03:15 PM Healthcare NSE: ONEGLOBAL

One Global Service Provider Li Share Price Update

As of the latest trading session, One Global Service Provider Li share price is currently at 354, which is down by -7.20 from its previous closing. Today, the stock has fluctuated between 354.00 and 354.00. Over the past year, One Global Service Provider Li has achieved a return of 353.59 %. In the last month alone, the return has been 27.36 %. Read More...

One Global Service Provider Li Performance

Day Range

Low354.00 High354.00

354.00

52 Week Range

Low 76.00 High 407.60

354.00

One Global Service Provider Li Share Price

514330

ONEGLOBAL

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

354.00 Prev. Close

361.20 Volume (Shares)

2314.00

Total traded value

8.19 Upper Circuit

361.05 Lower Circuit

346.95

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

One Global Service Provider Li Fundamentals

(Standalone)

Market Cap (Cr)	251.30
PE Ratio (TTM)	22.35
Book Value / Share	25.94
Beta	0.06

ROE	59.75%
EPS (TTM)	16.16
Dividend Yield	0.28%
Net Profit Qtr (Cr)	3.48

One Global Service Provider Li Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	33.37
Operating Expense	28.61
Net Profit	3.48
Net Profit Margin (%)	10.42
Earnings Per Share (EPS)	4.89
EBITDA	4.81
Effective Tax Rate (%)	27.04

Particulars	SEP 2024 (Values in Cr)
Revenue	19.41
Operating Expense	16.39
Net Profit	2.27
Net Profit Margin (%)	11.69
Earnings Per Share (EPS)	3.19
EBITDA	3.07
Effective Tax Rate (%)	25.08

Particulars	JUN 2024 (Values in Cr)
Revenue	13.56
Operating Expense	11.24
Net Profit	1.76
Net Profit Margin (%)	12.97
Earnings Per Share (EPS)	2.47
EBITDA	2.36
Effective Tax Rate (%)	24.13

Particulars	MAR 2024 (Values in Cr)
Revenue	24.30
Operating Expense	18.98
Net Profit	3.97
Net Profit Margin (%)	16.33
Earnings Per Share (EPS)	5.59
EBITDA	5.39
Effective Tax Rate (%)	25.32

Particulars	DEC 2023 (Values in Cr)
Revenue	14.54
Operating Expense	12.59
Net Profit	1.46
Net Profit Margin (%)	10.04
Earnings Per Share (EPS)	2.06
EBITDA	2.01
Effective Tax Rate (%)	25.12

Particulars	MAR 2024 (Values in Cr)
Revenue	63.01
Operating Expense	53.51
Net Profit	7.11
Net Profit Margin (%)	11.28
Earnings Per Share (EPS)	10.01
EBITDA	9.73
Effective Tax Rate (%)	25.15

Particulars	MAR 2023 (Values in Cr)
Revenue	18.12
Operating Expense	16.76
Net Profit	1.38
Net Profit Margin (%)	7.61
Earnings Per Share (EPS)	1.94
EBITDA	1.65
Effective Tax Rate (%)	-1.47

Particulars	MAR 2022 (Values in Cr)
Revenue	6.08
Operating Expense	5.07
Net Profit	1.02
Net Profit Margin (%)	16.77
Earnings Per Share (EPS)	1.43
EBITDA	1.35
Effective Tax Rate (%)	0.00

Particulars	MAR 2021 (Values in Cr)
Revenue	3.67
Operating Expense	1.34
Net Profit	2.33
Net Profit Margin (%)	63.48
Earnings Per Share (EPS)	3.28
EBITDA	2.45
Effective Tax Rate (%)	0.00

Particulars	MAR 2020 (Values in Cr)
Revenue	0.00
Operating Expense	0.30
Net Profit	-0.30
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.43
EBITDA	-0.16
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	20.27
ROE %	59.75
ROCE %	77.53
Total Debt to Total Equity	0.03
EBITDA Margin	15.43

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	10.26
ROE %	14.68
ROCE %	14.07
Total Debt to Total Equity	0.05
EBITDA Margin	9.16

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	8.32
ROE %	11.17
ROCE %	10.68
Total Debt to Total Equity	0.06
EBITDA Margin	22.70

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	6.84
ROE %	47.55
ROCE %	45.66
Total Debt to Total Equity	0.11
EBITDA Margin	67.85

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	0.57
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.38
EBITDA Margin	0.00

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	1.22
Total Assets	31.80
Total Liabilities	31.80
Total Equity	14.39
Share Outstanding	7104707
Price to Book Ratio	3.86
Return on Assets (%)	22.34
Return on Capital (%)	48.23

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	0.02
Total Assets	12.82
Total Liabilities	12.82
Total Equity	7.29
Share Outstanding	7104707
Price to Book Ratio	3.10
Return on Assets (%)	10.75
Return on Capital (%)	18.08

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	0.04
Total Assets	8.50
Total Liabilities	8.50
Total Equity	5.91
Share Outstanding	7104707
Price to Book Ratio	4.72
Return on Assets (%)	12.33
Return on Capital (%)	16.79

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	0.07
Total Assets	6.50
Total Liabilities	6.50
Total Equity	4.86
Share Outstanding	7104707
Price to Book Ratio	0.72
Return on Assets (%)	35.86
Return on Capital (%)	44.85

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.03
Total Assets	2.92
Total Liabilities	2.92
Total Equity	2.52
Share Outstanding	7104707
Price to Book Ratio	5.74
Return on Assets (%)	-10.33
Return on Capital (%)	-10.93

Particulars	MAR 2024 (Values in Cr)
Net Income	9.49
Cash from Operations	1.21
Cash from Investing	-0.01
Cash from Financing	0.00
Net change in Cash	1.19
Free Cash Flow	1.22

Particulars	MAR 2023 (Values in Cr)
Net Income	1.35
Cash from Operations	0.13
Cash from Investing	-0.16
Cash from Financing	0.00
Net change in Cash	-0.02
Free Cash Flow	0.30

Particulars	MAR 2022 (Values in Cr)
Net Income	1.01
Cash from Operations	0.51
Cash from Investing	-0.54
Cash from Financing	0.00
Net change in Cash	-0.02
Free Cash Flow	1.05

Particulars	MAR 2021 (Values in Cr)
Net Income	2.33
Cash from Operations	1.10
Cash from Investing	-0.89
Cash from Financing	0.10
Net change in Cash	0.04
Free Cash Flow	1.99

Particulars	MAR 2020 (Values in Cr)
Net Income	-0.30
Cash from Operations	-0.01
Cash from Investing	0.00
Cash from Financing	0.05
Net change in Cash	0.02
Free Cash Flow	-0.01

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
APOLLO HOSPITALS ENTER. L	6772.20	74.32	12.99	97373.85	5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED	84.48	206.05	5.30	158.33	51.01 / 107.94
SHREE PACETRONIX LTD.	73.00	15.21	1.95	26.28	61.11 / 268.50
TRANSGENE BIOTEK LTD.	3.65	0.00	2.55	27.66	3.22 / 10.84
VIMTA LABS LIMITED	917.95	33.58	5.95	2041.02	420.00 / 1183.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
APOLLO HOSPITALS ENTER. L	6772.20	81.03	11.88	97373.85	5690.80 / 7545.10
Surlux Diagnostic Ltd	1.40	0.84	0.13	0.49	0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL	32.40	0.00	-17.35	24.20	28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA	5499.65	29.15	6.18	6016.62	3750.00 / 6400.00

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 372.50
26 Days 343.70
10 Days 369.50
50 Days 322.10
12 Days 366.10
100 Days 289.00
20 Days 352.10
200 Days 236.60

361.20
PIVOT

First Resistance	361.20
Second Resistance	361.20
Third Resistance	361.20

First Support	361.20
Second Support	361.20
Third Support	361.20

RSI	57.55
MACD	22.46
Commodity Channel Index (CCI)	30.43

ADX	26.05
Williams % R	-48.89

One Global Service Provider Li Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

55.51 Promoter Holdings

29.5 FII

14.97 DII

0.0 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Vijay Nanaji Dhawangale	Shareholding of Promoter and Promoter Group	1051021.0	14.79
Sona V Dhawangale	Shareholding of Promoter and Promoter Group	1045411.0	14.71
Ag Dynamic Funds Limited	Public Shareholding	312346.0	4.4
Minal Amol Kale	Public Shareholding	302981.0	4.26
Sushma Deepak Kanse	Public Shareholding	232441.0	3.27
Sarang Arun Landge	Public Shareholding	226410.0	3.19
Nexpact Limited	Public Shareholding	215703.0	3.04
Nexpact Limited	Public Shareholding	215703.0	3.04
Saurabh Vijayrao Mahurkar	Public Shareholding	167319.0	2.36
Indrajit Yashwant Shinde	Public Shareholding	94667.0	1.33
Jamnalal Kasturchand Kabra	Public Shareholding	73800.0	1.04
Navdeep Goyal	Shareholding of Promoter and Promoter Group	0.0	0.0
Shubharangana Goyal	Shareholding of Promoter and Promoter Group	0.0	0.0
Naresh Goyal	Shareholding of Promoter and Promoter Group	0.0	0.0
Minal Aggarwal	Shareholding of Promoter and Promoter Group	0.0	0.0
Kamal Aggarwal	Shareholding of Promoter and Promoter Group	0.0	0.0

One Global Service Provider Li

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read